Tontini Gian Eugenio, Rimondi Alessandro, Vernero Marta, Neumann Helmut, Vecchi Maurizio, Bezzio Cristina, Cavallaro Flaminia
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Organ Transplantation, Università degli Studi di Milano, Via Francesco Sforza 35, Milano 20122, Italy.
Therap Adv Gastroenterol. 2021 Jun 10;14:17562848211017730. doi: 10.1177/17562848211017730. eCollection 2021.
Since the advent of artificial intelligence (AI) in clinical studies, luminal gastrointestinal endoscopy has made great progress, especially in the detection and characterization of neoplastic and preneoplastic lesions. Several studies have recently shown the potential of AI-driven endoscopy for the investigation of inflammatory bowel disease (IBD). This systematic review provides an overview of the current position and future potential of AI in IBD endoscopy.
A systematic search was carried out in PubMed and Scopus up to 2 December 2020 using the following search terms: artificial intelligence, machine learning, computer-aided, inflammatory bowel disease, ulcerative colitis (UC), Crohn's disease (CD). All studies on human digestive endoscopy were included. A qualitative analysis and a narrative description were performed for each selected record according to the Joanna Briggs Institute methodologies and the PRISMA statement.
Of 398 identified records, 18 were ultimately included. Two-thirds of these (12/18) were published in 2020 and most were cross-sectional studies (15/18). No relevant bias at the study level was reported, although the risk of publication bias across studies cannot be ruled out at this early stage. Eleven records dealt with UC, five with CD and two with both. Most of the AI systems involved convolutional neural network, random forest and deep neural network architecture. Most studies focused on capsule endoscopy readings in CD ( = 5) and on the AI-assisted assessment of mucosal activity in UC ( = 10) for automated endoscopic scoring or real-time prediction of histological disease.
AI-assisted endoscopy in IBD is a rapidly evolving research field with promising technical results and additional benefits when tested in an experimental clinical scenario. External validation studies being conducted in large and prospective cohorts in real-life clinical scenarios will help confirm the added value of AI in assessing UC mucosal activity and in CD capsule reading.
Artificial intelligence (AI) is a promising technology in many areas of medicine. In recent years, AI-assisted endoscopy has been introduced into several research fields, including inflammatory bowel disease (IBD) endoscopy, with promising applications that have the potential to revolutionize clinical practice and gastrointestinal endoscopy.We have performed the first systematic review of AI and its application in the field of IBD and endoscopy.A formal process of paper selection and analysis resulted in the assessment of 18 records. Most of these (12/18) were published in 2020 and were cross-sectional studies (15/18). No relevant biases were reported. All studies showed positive results concerning the novel technology evaluated, so the risk of publication bias cannot be ruled out at this early stage.Eleven records dealt with UC, five with CD and two with both. Most studies focused on capsule endoscopy reading in CD patients ( = 5) and on AI-assisted assessment of mucosal activity in UC patients ( = 10) for automated endoscopic scoring and real-time prediction of histological disease.We found that AI-assisted endoscopy in IBD is a rapidly growing research field. All studies indicated promising technical results. When tested in an experimental clinical scenario, AI-assisted endoscopy showed it could potentially improve the management of patients with IBD.Confirmatory evidence from real-life clinical scenarios should be obtained to verify the added value of AI-assisted IBD endoscopy in assessing UC mucosal activity and in CD capsule reading.
自人工智能(AI)应用于临床研究以来,腔内胃肠内镜检查取得了巨大进展,尤其是在肿瘤性和癌前病变的检测与特征描述方面。最近的几项研究显示了人工智能驱动的内镜检查在炎症性肠病(IBD)研究中的潜力。本系统评价概述了人工智能在IBD内镜检查中的当前地位和未来潜力。
截至2020年12月2日,在PubMed和Scopus中进行了系统检索,使用以下检索词:人工智能、机器学习、计算机辅助、炎症性肠病、溃疡性结肠炎(UC)、克罗恩病(CD)。纳入所有关于人类消化内镜检查的研究。根据乔安娜·布里格斯研究所的方法和PRISMA声明,对每条选定记录进行定性分析和叙述性描述。
在398条识别出的记录中,最终纳入18条。其中三分之二(12/18)于2020年发表,且大多数为横断面研究(15/18)。尽管在这一早期阶段不能排除跨研究发表偏倚的风险,但未报告研究层面的相关偏倚。11条记录涉及UC,5条涉及CD,2条同时涉及两者。大多数人工智能系统涉及卷积神经网络、随机森林和深度神经网络架构。大多数研究集中于CD中的胶囊内镜读数(n = 5)以及UC中人工智能辅助的黏膜活性评估(n = 10),用于自动内镜评分或组织学疾病的实时预测。
IBD中的人工智能辅助内镜检查是一个快速发展的研究领域,在实验临床场景中进行测试时具有令人鼓舞的技术成果和额外益处。在现实临床场景中的大型前瞻性队列中进行的外部验证研究将有助于确认人工智能在评估UC黏膜活性和CD胶囊内镜读数方面的附加价值。
人工智能(AI)在医学的许多领域都是一项有前景的技术。近年来,人工智能辅助内镜检查已被引入多个研究领域,包括炎症性肠病(IBD)内镜检查,其应用前景广阔,有可能彻底改变临床实践和胃肠内镜检查。我们对人工智能及其在IBD和内镜检查领域的应用进行了首次系统评价。一个正式的论文筛选和分析过程导致对18条记录进行了评估。其中大多数(12/18)于2020年发表,且为横断面研究(15/18)。未报告相关偏倚。所有研究均显示了关于所评估的新技术的阳性结果,因此在这一早期阶段不能排除发表偏倚的风险。11条记录涉及UC,5条涉及CD,2条同时涉及两者。大多数研究集中于CD患者的胶囊内镜读数(n = 5)以及UC患者的人工智能辅助黏膜活性评估(n = 10),用于自动内镜评分和组织学疾病的实时预测。我们发现IBD中的人工智能辅助内镜检查是一个快速发展的研究领域。所有研究均显示了令人鼓舞的技术成果。在实验临床场景中进行测试时,人工智能辅助内镜检查显示其有可能改善IBD患者的管理。应从现实临床场景中获得确证性证据,以验证人工智能辅助IBD内镜检查在评估UC黏膜活性和CD胶囊内镜读数方面的附加价值。